Military Metals Retires 1% NSR with CAD$162,800 Buyback and Reports 23.2 m of 2.22% Sb
Military Metals paid CAD$162,800 to retire a 1% net smelter royalty covering its three Slovakian portfolio assets, including Trojarová, Tiennesgrund and Medvedi Potok, making them royalty-free. Initial Trojarová drilling returned 23.2 m at 2.22% Sb including 7.9 m at 4.9% Sb and 23.2 m at 1.27 g/t Au, including 6.2 m at 3.17 g/t Au.
1. Royalty Buyback Strengthens Slovakian Portfolio
Military Metals Corp. has completed the cash buyback of a 1% net smelter royalty (NSR) on its Slovakian portfolio, retiring royalty obligations on three key assets: the Trojarová Antimony Gold Project, the Tiennesgrund Antimony Gold Project, and the Medvedi Potok Tin Project. The Company’s wholly-owned subsidiary executed the buyback under the terms of a pre-existing share purchase agreement, paying CAD 162,800 in a one-time cash consideration. With this transaction, all three projects are now royalty-free, eliminating future NSR payments and enhancing the economic upside and strategic value of the portfolio as Military Metals advances exploration and resource definition work.
2. Drill Results Validate Trojarová’s Resource Potential
In its first definition hole (25-TVA-001) at the 100%-owned Trojarová Project, Military Metals reported 23.2 metres grading 2.22% antimony over a 20.1-metre true width (from 144.3m to 167.5m), including a higher-grade sub-interval of 7.9 metres at 4.9% Sb over a 6.8-metre true width (152.7m to 160.6m). The same interval returned 23.2 metres of 1.27 g/t gold (true width 20.1m), with a 6.2-metre zone grading 3.17 g/t Au (true width 5.4m from 160.6m to 166.8m). These modern assays confirm historical drilling and provide critical data for SLR Consulting’s forthcoming Mineral Resource Estimate, expected later this quarter. Management highlights that these results support continuity and enrichment trends in both antimony and gold mineralization, reinforcing Trojarová’s potential as Europe’s only extensively drilled antimony asset backed by contemporary assays.